Liver metastases are common in oncologic patients, causing substantial morbidity and mortality. Systemic therapy is now standard palliative treatment for most patients with liver metastases, often providing transient responses and increased overall survival. In selected oligometastatic patients, local treatment can lead to long disease-free intervals and even permanent disease control. Although surgery remains the gold standard of local treatments, most patients will not be appropriate surgical candidates. For these patients, alternate local treatments have been developed. Among these, stereotactic body radiotherapy (SBRT) presents an attractive non-invasive option for selected patients with limited hepatic involvement. This article reviews the development, indications, methods, and results of SBRT in the management of liver metastases.
The liver is a common site of metastatic disease from some of the most prevalent malignancies, in particular gastrointestinal tumors for which metastatic deposits travel through the portal venous system. Approximately one-third of patients with solid tumors will develop liver metastases. In a large autopsy series the prevalence of liver involvement was 86 % for pancreatic cancer, 60 % for breast cancer, and 42 % in colorectal cancer. 1 Hepatic involvement is often life-limiting and can result in severe morbidity. Approximately half of metastatic deaths from breast and prostate cancers are associated with liver metastases. Death due to colorectal cancer is frequently related to liver metastases, often as the only site of metastatic disease.
Background to the Role of Stereotactic Body Radiotherapy

Ablative Therapy of Liver Metastases
Systemic therapy is usually the primary therapy for metastatic liver disease, 2 as it may allow for transitory responses and increased median survival. For patients with metastatic colorectal cancer treated with current palliative chemotherapy, median survival now approaches two years. 3 Although whole liver radiotherapy has long been abandoned as an anti-cancer therapy, current (infrequent) use in symptomatic patients may still offer symptomatic relief. 4 The goal of aggressive local treatment is long-term disease control for selected patients. [5] [6] [7] [8] Its benefits are now supported by large retrospective series. With a long history, surgical resection remains the gold standard local treatment of hepatic metastases-typically of colorectal origin. 2, 9 Surgery is associated with an acute risk of death (typically in less than 5 %) 10 but can lead to five-year overall survival rates of up to 58 %. (19-36 Gy to whole liver), symptoms were reduced in over half the patients. 17 A subsequent Radiation Therapy Oncology Group dose escalating trial (84-05) reported dose-dependant liver toxicity with a 10 % actuarial risk of severe liver toxicity at six months when whole-liver dose was increased from 27-33 Gy.
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In addition to total dose, liver tolerance to radiotherapy depends on underlying liver function, treatment volume, and dose fractionation.
Patients with liver metastases are thus typically more tolerant than patients with primary liver tumors-where underlying liver cirrhosis is common. In standard fractionation (1.8-2 Gy per day) severe hepatic toxicity occurs with increasing frequency at whole-liver doses of ≥36 Gy.
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Radiation-induced liver disease (RILD) arises four to eight weeks after radiation therapy, manifesting with weight gain, increased abdominal girth, ascites, and a severe increase of alkaline phosphatase, with an associated mortality rate of 10-20 %. Pathophysiologically, RILD manifests as a veno-occlusive disease, liver architecture distortion, and fibrosis. 9 Unfortunately, doses of 30-36 Gy are insufficient for tumor ablation.
Advances in imaging and radiotherapy have made partial liver irradiation feasible, allowing for differential dosing of tumor and normal liver.
Stereotactic body radiotherapy can be defined as 'a radiation therapy method used to very precisely deliver a high dose of radiation to an extracranial target within the body, using either a single dose or a small number of fractions'. It allows delivery of high doses per fraction to small volumes with geographic sparing of adjacent organs at risk, applying the principles of radiosurgery, long used for brain tumors. Although mean liver dose is a strong predictor of toxicity, the 'threshold hypothesis' of Jackson et al. 21 would predict that the risk of RILD can be kept low, independently from the prescribed dose, as long as a certain volume of liver is spared. This is borne out by the work of Dawson et al. demonstrating clinically that much higher doses of radiation can be delivered to small liver volumes-beyond 100 Gy when the irradiated volume represents less than 25 % of the liver.
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Technical Challenges of Partial Liver Irradiation with Stereotactic Body Radiotherapy
Breathing Motion
Specific technical issues arise when irradiating focal liver targets, the most obvious and problematic is dealing with motion due to breathing. During each treatment, precise patient positioning is attained using image-guidance (so-called image-guided radiotherapy) with 3D, 4D, and/or planar imaging.
Case Selection
Patient selection is important. The best candidates for SBRT are patients with more than 1,000 cm 3 of healthy liver and few (<3-4) reasonably-sized (<6 cm) lesions which do not touch the colon or duodenum (see Figure 2) . It is not rare for SBRT to complement a treatment plan where a caudate metastasis is irradiated and other tumors are dealt with using surgery or RFA. Poor candidates for SBRT have small or cirrhotic livers, numerous (>4) lesions, or lesions in broad contact with the bowel. If SBRT is used in these cases the risk of toxicity will be greater and the probability of ablation will be lower. There is an art to case selection but general guidelines are outlined in Table 1 .
Clinical Outcomes with Liver Stereotactic Body Radiotherapy
Clinical Reports
The 38 One patient developed fatal-possibly iatrogenic-liver failure, two patients had duodenal ulcerations, and one, colonic ulceration. In addition, other mild to moderate toxicities were observed.
Local control rates at one and two years were 89 and 79 %, with threeand five-year overall survival rates of 22 and 13 %. We reported our experience with 21 patients treated with SBRT for liver metastases with median dose 40 Gy (20-50 Gy) in one to 10 fractions. 42 Treatment was well tolerated and toxicity was mild with the exception of one case of transient colitis. Actuarial overall one-and two-year survival rates were 94 and 60% and actuarial one-and two-year local control rates were 62 %.
Toxicity
After initial reports of severe bowel or liver toxicity, most contemporary trials incorporating specific normal tissue dose constraints typically report mild toxicity. Organ tolerance to focal radiation with short treatment schemes is however still incompletely understood. A Phase I multicenter prospective study was performed in the US to test the maximum tolerated dose (MTD) of SBRT for liver metastases. 43 Eighteen patients were enrolled, four of which had multiple tumors. The initial prescribed dose was 36 Gy in three fractions, with subsequent cohorts receiving a dose escalation of 2 Gy per fraction up to 60 Gy in three fractions or MTD. The MTD was not reached and a Phase II study was initiated. Kavanagh et al.
reported an interim analysis of the combined Phase I/II study, including the 18 patients from Phase I (doses of 36-60 Gy in three fractions) and another 18 patients treated to 60 Gy in the Phase II component. 44 A high rate of durable in-field tumor control was achieved with only one case of grade 3 toxicity (no grade 4). In an expanded cohort, actuarial in-field local control rate at one and two tears were 95 and 92%, respectively, and two-year local control for lesions with 3 cm or less of 100 %. treatment, and follow-up heterogeneity across studies. Table 2 summarizes results of selected series. As with other local therapies, prospective evidence for an impact on overall survival is lacking for SBRT. 40 Survival will be heterogeneous in these patients' populations and depend on patient, disease, and treatment factors. Actuarial survival at one to two years with SBRT has been reported to range from 71-94 % and 30-62 %. 41 Fractionation for these treatments varies among studies, from single dose to 10 fractions, and associated total doses of 14-60 Gy. Forty-five Gy in three fractions or 50 Gy in five fractions (over one to two weeks on non-consecutive days) are commonly used regimens.
Future Directions
Based on the results from published series, SBRT has evolved to a feasible, safe, and effective non-invasive treatment for selected liver metastases, complementing present treatment options. As these treatments become more widely available, published cohorts will become more substantive and the now heterogeneous treatment regimens will likely become better standardized. In an effort to help sort out the effect of number of sessions, the Stereotactic radiation therapy of liver metastases (StRaL) trial proposes to randomize patients with one to three lesions to a single dose of 28 Gy versus a hypofractionated approach with 3 x 12.5 Gy. Associations of chemotherapy or targeted therapy, will also likely be investigated in future trials. For now, clinical judgment is used in the timing of systemic therapy and SBRT. The most prudent physicians will prefer an interval of several weeks before and after SBRT, in other cases SBRT may be delivered on a normal 'off week' seen in many regimens or even concurrently with agents which are not strong radiation sensitizers.
In upcoming years, we expect to see evaluation of this technique in the treatment of oligometastases in cancers where ablative therapy of metastases is not yet a widespread standard (small cell lung, for example). Another direction is prospective comparison to other local modalities. In this sense, the most mature project is the ongoing Radiofrequency ablation versus stereotactic body radiation (RAS) trial, a multicenter randomized prospective trial for colorectal liver metastases.
Patients are eligible for this trial if they are not suitable for surgical resection, and have one to four metastases with maximum 4 cm diameter, amenable to both RFA and SBRT. n
